Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors-Reference-Cited by-同舟云学术

Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors

Published:2007-05-17 Issue:4 Volume:24 Page:372-378
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Rubenstein Marvin,Tsui Paulus,Guinan Patrick

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-007-0023-y.pdf

Reference18 articles.

1. Rubenstein M, Tsui P, Guinan P. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses 2005;65:905–7.

2. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Exp Clin Pharmacol 2006;28:1–4.

3. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. (In Press Med Oncol 2007:24).

4. Rubenstein M, Anderson KM, Tsui P, Guinan P. Synthesis of branched antisense oligonucleotides having multiple specificities: treatment of hormone insensitive prostate cancer. Med Hypotheses 2006;67:1374–79.

5. Rubenstein M, Mirochnik Y, Chou P, Guinan P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 1996;62:194–200.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNase H-sensitive multifunctional ASO-based constructs as promising tools for the treatment of multifactorial complex pathologies;Bioorganic Chemistry;2024-09

2. In LNCaP Cells Inhibition of BCL-2 by Antisense Oligonucleonucleotides Results in Compensatory Changes in Apoptosis;Scientific Journal of Genetics and Gene Therapy;2014-03-27

3. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR;Medical Oncology;2011-05-15

4. Anionic long‐circulating liposomes for delivery of radioiodinated antisense oligonucleotides;European Journal of Lipid Science and Technology;2010-05

5. Bax expression remains unchanged following antisense treatment directed against BCL-2;Medical Oncology;2010-04-27